These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17564092)

  • 1. [Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement].
    Ohno N; Fujiyama S; Ooi M; Haraguchi K; Tokunaga M; Uozumi K; Tsubouchi H
    Nihon Naika Gakkai Zasshi; 2007 May; 96(5):988-90. PubMed ID: 17564092
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
    Arita Y; Sakata Y; Sudo T; Maeda T; Matsuoka K; Tamai K; Higuchi K; Shioyama W; Nakaoka Y; Kanakura Y; Yamauchi-Takihara K
    Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N; Arai T; Kitaichi M; Inoue Y
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24072826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
    J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M; Yasuoka H; Takeuchi T
    Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
    Mûzes G; Csomor J; Sipos F
    Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
    Taniguchi K; Shimazaki C; Fujimoto Y; Shimura K; Uchiyama H; Matsumoto Y; Kuroda J; Horiike S; Taniwaki M
    Int J Hematol; 2009 Jul; 90(1):99-102. PubMed ID: 19554396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K; Murayama S; Ito H; Koga T
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
    Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
    Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
    Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
    Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
    Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
    Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease.
    Nishioka H; Takegawa H; Kamei H
    J Infect Chemother; 2018 Feb; 24(2):138-141. PubMed ID: 29021093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.